Annual Drug Patent Expirations for INCRUSE+ELLIPTA
Incruse Ellipta is a drug marketed by Glaxo Grp England and is included in one NDA. It is available from one supplier. There are ten patents protecting this drug.
INCRUSE ELLIPTA drug price trends.
This drug has one hundred and fifty-four patent family members in thirty-nine countries.
The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. One supplier is listed for this compound. Additional details are available on the umeclidinium bromide profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com